Watts Ryan J.'s Form 4 filing
Denali Therapeutics Inc.DNLI · filed Jul 11, 2025
- Accession no.
- 0001714899-25-000149
- Filed
- Jul 11, 2025
- Trade date
- Jul 9, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $7.43M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watts Ryan J.CIK 0001724310 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 9, 2025 | Common Stock | MOption exerciseAcquired | +455,282 | $0.68 | +$309,591.76 | 708,353 | Direct | |
| Jul 9, 2025 | Common Stock | MOption exerciseAcquired | +40,000 | $5.28 | +$211,200 | 748,353 | Direct | |
| Jul 9, 2025 | Common Stock | SSaleDisposed | −495,282 | $15.00F3 | −$7,429,230 | 253,071 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 9, 2025 | Common Stock | MOption exerciseDisposed | −455,282 | $0.00 | $0 | 622,809 | Direct | |
| Jul 9, 2025 | Common Stock | MOption exerciseDisposed | −40,000 | $0.00 | $0 | 20,369 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $15.00 to $15.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.